The reason for delayed drug development in a particular disease typically falls into one of two. It’s either low awareness of the disease or challenges to drug development.

Despite falling into these two categories, 'Camzyos (mavacamten)' was developed. It is a first-in-class targeted treatment option for obstructive hypertrophic cardiomyopathy (oHCM).

oHCM is a rare heart disease characterized by thickened heart muscles that cause narrowing or obstruction of the left ventricular outflow tract (LVOT). Not only does it cause abnormality in heart structure, but it decreases heart function. The symptoms include shortness of breath, chest pain, dizziness, and fainting. It is a fatal